insulin glargine+ glulisine + NPH + Regular insulin
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diabetic Ketoacidosis
Conditions
Diabetic Ketoacidosis
Trial Timeline
Dec 1, 2007 → Aug 1, 2008
NCT ID
NCT00590044About insulin glargine+ glulisine + NPH + Regular insulin
insulin glargine+ glulisine + NPH + Regular insulin is a approved stage product being developed by Sanofi for Diabetic Ketoacidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00590044. Target conditions include Diabetic Ketoacidosis.
What happened to similar drugs?
20 of 20 similar drugs in Diabetic Ketoacidosis were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00590044 | Approved | Completed |
Competing Products
20 competing products in Diabetic Ketoacidosis